 Katherine Rennie
Concepts (208)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hair Cells, Vestibular | 21 | 2024 | 29 | 6.400 |
Why?
| | Potassium | 11 | 2024 | 137 | 1.930 |
Why?
| | Potassium Channels | 8 | 2024 | 144 | 1.690 |
Why?
| | Action Potentials | 9 | 2023 | 468 | 1.650 |
Why?
| | Gerbillinae | 18 | 2024 | 64 | 1.460 |
Why?
| | Sodium | 7 | 2024 | 205 | 1.310 |
Why?
| | Vestibule, Labyrinth | 5 | 2023 | 66 | 1.300 |
Why?
| | Hair Cells, Ampulla | 2 | 2024 | 3 | 1.270 |
Why?
| | Neurons, Afferent | 5 | 2024 | 86 | 1.240 |
Why?
| | Membrane Potentials | 13 | 2024 | 260 | 1.220 |
Why?
| | Mechanotransduction, Cellular | 3 | 2024 | 110 | 1.140 |
Why?
| | Nasal Obstruction | 3 | 2024 | 25 | 1.090 |
Why?
| | Patch-Clamp Techniques | 13 | 2024 | 261 | 0.970 |
Why?
| | Ear, Inner | 2 | 2016 | 44 | 0.950 |
Why?
| | Sarcopenia | 2 | 2025 | 74 | 0.940 |
Why?
| | Excitatory Postsynaptic Potentials | 2 | 2017 | 112 | 0.910 |
Why?
| | Fluoxetine | 1 | 2024 | 52 | 0.880 |
Why?
| | Frailty | 2 | 2025 | 153 | 0.840 |
Why?
| | Presynaptic Terminals | 3 | 2024 | 68 | 0.820 |
Why?
| | Sodium Channels | 3 | 2024 | 62 | 0.790 |
Why?
| | Metformin | 2 | 2025 | 312 | 0.790 |
Why?
| | Nasal Septum | 3 | 2024 | 24 | 0.780 |
Why?
| | Sodium Channel Blockers | 2 | 2020 | 23 | 0.780 |
Why?
| | Tetrodotoxin | 2 | 2020 | 38 | 0.780 |
Why?
| | Ion Channels | 3 | 2012 | 127 | 0.770 |
Why?
| | Vestibular Nerve | 1 | 2020 | 16 | 0.700 |
Why?
| | NAV1.6 Voltage-Gated Sodium Channel | 1 | 2020 | 10 | 0.700 |
Why?
| | Nose Deformities, Acquired | 1 | 2020 | 3 | 0.680 |
Why?
| | Resistance Training | 1 | 2022 | 151 | 0.650 |
Why?
| | Rhinoplasty | 1 | 2020 | 27 | 0.650 |
Why?
| | Conservative Treatment | 1 | 2020 | 33 | 0.650 |
Why?
| | Receptors, AMPA | 2 | 2017 | 133 | 0.610 |
Why?
| | Semicircular Canals | 5 | 2009 | 29 | 0.600 |
Why?
| | Potassium Channel Blockers | 5 | 2014 | 34 | 0.570 |
Why?
| | 4-Aminopyridine | 7 | 2024 | 22 | 0.530 |
Why?
| | Hair Cells, Auditory | 5 | 2016 | 41 | 0.510 |
Why?
| | Hair Cells, Auditory, Inner | 2 | 2009 | 14 | 0.460 |
Why?
| | Neomycin | 1 | 2013 | 7 | 0.440 |
Why?
| | Animals | 30 | 2024 | 34479 | 0.430 |
Why?
| | Gentamicins | 1 | 2013 | 52 | 0.420 |
Why?
| | Anthracenes | 3 | 2014 | 31 | 0.400 |
Why?
| | Apamin | 1 | 2011 | 6 | 0.390 |
Why?
| | Small-Conductance Calcium-Activated Potassium Channels | 1 | 2011 | 9 | 0.380 |
Why?
| | Synapses | 2 | 2017 | 383 | 0.370 |
Why?
| | Calcium | 5 | 2011 | 1178 | 0.320 |
Why?
| | Columbidae | 7 | 2004 | 30 | 0.300 |
Why?
| | Cations | 2 | 2016 | 79 | 0.290 |
Why?
| | Ion Channel Gating | 2 | 2005 | 87 | 0.290 |
Why?
| | Cells, Cultured | 6 | 2017 | 4001 | 0.270 |
Why?
| | Cell Membrane | 2 | 2016 | 720 | 0.270 |
Why?
| | Potassium Channels, Voltage-Gated | 1 | 2005 | 48 | 0.240 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2022 | 1356 | 0.240 |
Why?
| | England | 2 | 2025 | 72 | 0.230 |
Why?
| | Vestibular Diseases | 1 | 2024 | 25 | 0.230 |
Why?
| | Dizziness | 1 | 2024 | 80 | 0.220 |
Why?
| | Physical Stimulation | 1 | 2004 | 74 | 0.220 |
Why?
| | Mammals | 2 | 2023 | 268 | 0.220 |
Why?
| | Anti-Bacterial Agents | 1 | 2013 | 1663 | 0.210 |
Why?
| | Models, Neurological | 2 | 2005 | 236 | 0.210 |
Why?
| | Double-Blind Method | 3 | 2025 | 1848 | 0.210 |
Why?
| | Electric Conductivity | 5 | 2004 | 95 | 0.180 |
Why?
| | Cost-Benefit Analysis | 2 | 2024 | 567 | 0.180 |
Why?
| | Female | 14 | 2025 | 68153 | 0.180 |
Why?
| | Male | 11 | 2025 | 62857 | 0.180 |
Why?
| | Steroids, Fluorinated | 1 | 2020 | 1 | 0.170 |
Why?
| | Scotland | 1 | 2020 | 12 | 0.170 |
Why?
| | Wales | 1 | 2020 | 17 | 0.170 |
Why?
| | Administration, Intranasal | 1 | 2020 | 82 | 0.170 |
Why?
| | Clinical Trials, Phase III as Topic | 1 | 2020 | 90 | 0.170 |
Why?
| | Electrophysiology | 5 | 2009 | 204 | 0.160 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 285 | 0.150 |
Why?
| | Indoles | 1 | 2001 | 371 | 0.150 |
Why?
| | Endoscopy | 1 | 2020 | 266 | 0.140 |
Why?
| | Benzothiadiazines | 1 | 2017 | 3 | 0.140 |
Why?
| | 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester | 1 | 2017 | 11 | 0.140 |
Why?
| | Strontium | 1 | 2017 | 14 | 0.140 |
Why?
| | Pyridines | 1 | 2001 | 475 | 0.140 |
Why?
| | Nifedipine | 1 | 2017 | 28 | 0.140 |
Why?
| | Clinical Decision-Making | 1 | 2020 | 304 | 0.140 |
Why?
| | Dipeptides | 1 | 2017 | 48 | 0.140 |
Why?
| | Quinoxalines | 1 | 2017 | 65 | 0.130 |
Why?
| | Calcium Channel Blockers | 1 | 2017 | 123 | 0.130 |
Why?
| | DNA, Mitochondrial | 2 | 2009 | 188 | 0.130 |
Why?
| | Hypoglycemic Agents | 1 | 2025 | 1212 | 0.130 |
Why?
| | Patient Selection | 1 | 2020 | 663 | 0.130 |
Why?
| | Ranidae | 1 | 2016 | 13 | 0.130 |
Why?
| | Chick Embryo | 1 | 2016 | 130 | 0.130 |
Why?
| | Calcium Channels, L-Type | 1 | 2017 | 113 | 0.130 |
Why?
| | Electrophysiological Phenomena | 1 | 2016 | 51 | 0.120 |
Why?
| | Neurotransmitter Agents | 1 | 2016 | 78 | 0.120 |
Why?
| | Coculture Techniques | 1 | 2016 | 226 | 0.120 |
Why?
| | Fishes | 1 | 2016 | 93 | 0.120 |
Why?
| | Birds | 1 | 2016 | 74 | 0.120 |
Why?
| | Self Report | 1 | 2020 | 801 | 0.120 |
Why?
| | Quality of Life | 3 | 2024 | 2680 | 0.120 |
Why?
| | Acetylcholine | 1 | 2016 | 181 | 0.120 |
Why?
| | Calcium Channels | 1 | 2016 | 152 | 0.120 |
Why?
| | Elapid Venoms | 1 | 2014 | 17 | 0.120 |
Why?
| | Beta vulgaris | 1 | 2014 | 11 | 0.120 |
Why?
| | Tissue Culture Techniques | 1 | 2014 | 68 | 0.110 |
Why?
| | Nitrates | 1 | 2014 | 87 | 0.110 |
Why?
| | Phytotherapy | 1 | 2014 | 75 | 0.110 |
Why?
| | Carrier Proteins | 1 | 1997 | 732 | 0.110 |
Why?
| | Choline | 1 | 2014 | 119 | 0.110 |
Why?
| | Steroids | 2 | 2024 | 147 | 0.100 |
Why?
| | Age Factors | 1 | 2020 | 3103 | 0.100 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 278 | 0.100 |
Why?
| | Treatment Outcome | 3 | 2024 | 10151 | 0.100 |
Why?
| | Cyclic GMP | 1 | 2012 | 85 | 0.100 |
Why?
| | Saccule and Utricle | 3 | 2004 | 6 | 0.100 |
Why?
| | Bee Venoms | 1 | 2011 | 8 | 0.100 |
Why?
| | Severity of Illness Index | 1 | 2020 | 2721 | 0.100 |
Why?
| | Cyclic AMP | 1 | 2012 | 229 | 0.090 |
Why?
| | Cesium | 3 | 2000 | 18 | 0.090 |
Why?
| | Adenosine Triphosphate | 1 | 1993 | 471 | 0.090 |
Why?
| | Nitric Oxide | 1 | 2016 | 882 | 0.090 |
Why?
| | Dietary Supplements | 1 | 2014 | 531 | 0.090 |
Why?
| | Guinea Pigs | 3 | 1997 | 155 | 0.080 |
Why?
| | Animals, Newborn | 1 | 2011 | 803 | 0.080 |
Why?
| | Pyrimidines | 1 | 2012 | 445 | 0.080 |
Why?
| | Humans | 9 | 2025 | 128417 | 0.080 |
Why?
| | Mitochondrial Diseases | 1 | 2009 | 88 | 0.080 |
Why?
| | Embryonic Stem Cells | 1 | 2009 | 119 | 0.080 |
Why?
| | Data Interpretation, Statistical | 1 | 2009 | 335 | 0.070 |
Why?
| | Blood Pressure | 1 | 2014 | 1728 | 0.070 |
Why?
| | Aged | 2 | 2025 | 21953 | 0.070 |
Why?
| | In Vitro Techniques | 3 | 1994 | 1039 | 0.070 |
Why?
| | NADH Dehydrogenase | 1 | 2006 | 18 | 0.060 |
Why?
| | Acidosis, Lactic | 1 | 2006 | 45 | 0.060 |
Why?
| | Hypertension | 1 | 2014 | 1235 | 0.060 |
Why?
| | Adult | 4 | 2024 | 35299 | 0.060 |
Why?
| | Point Mutation | 1 | 2006 | 223 | 0.060 |
Why?
| | Walking Speed | 1 | 2025 | 44 | 0.060 |
Why?
| | Potassium Channels, Inwardly Rectifying | 1 | 2004 | 31 | 0.060 |
Why?
| | Hand Strength | 1 | 2025 | 113 | 0.060 |
Why?
| | Tetraethylammonium Compounds | 2 | 1996 | 9 | 0.060 |
Why?
| | Turtles | 1 | 2004 | 11 | 0.060 |
Why?
| | Frail Elderly | 1 | 2025 | 121 | 0.060 |
Why?
| | Mice | 3 | 2016 | 16602 | 0.050 |
Why?
| | State Medicine | 1 | 2023 | 19 | 0.050 |
Why?
| | Cloning, Molecular | 1 | 2004 | 522 | 0.050 |
Why?
| | Mitochondria | 1 | 2009 | 848 | 0.050 |
Why?
| | Cell Differentiation | 1 | 2009 | 1900 | 0.050 |
Why?
| | Obesity | 1 | 2014 | 2858 | 0.050 |
Why?
| | Rats | 1 | 2009 | 5165 | 0.050 |
Why?
| | Capsaicin | 1 | 2001 | 25 | 0.050 |
Why?
| | Neurons | 1 | 2009 | 1448 | 0.040 |
Why?
| | Computer Simulation | 1 | 2005 | 939 | 0.040 |
Why?
| | Cell Division | 1 | 2001 | 778 | 0.040 |
Why?
| | Calcium Signaling | 1 | 2001 | 233 | 0.040 |
Why?
| | Aging | 1 | 2009 | 1750 | 0.040 |
Why?
| | Sensitivity and Specificity | 1 | 2004 | 1815 | 0.040 |
Why?
| | Sodium-Potassium-Chloride Symporters | 1 | 1997 | 9 | 0.040 |
Why?
| | Cell Separation | 3 | 1997 | 313 | 0.040 |
Why?
| | Kinetics | 2 | 1997 | 1615 | 0.030 |
Why?
| | Chlorides | 1 | 1997 | 138 | 0.030 |
Why?
| | Feeder Cells | 1 | 2016 | 3 | 0.030 |
Why?
| | Species Specificity | 2 | 1997 | 568 | 0.030 |
Why?
| | Clone Cells | 1 | 2016 | 255 | 0.030 |
Why?
| | Heterografts | 1 | 2016 | 129 | 0.030 |
Why?
| | Posture | 1 | 1996 | 176 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2004 | 2505 | 0.030 |
Why?
| | Cell Adhesion | 1 | 2016 | 445 | 0.030 |
Why?
| | Plant Preparations | 1 | 2014 | 30 | 0.030 |
Why?
| | Plant Roots | 1 | 2014 | 44 | 0.030 |
Why?
| | Beverages | 1 | 2014 | 67 | 0.030 |
Why?
| | Barium | 1 | 1994 | 27 | 0.030 |
Why?
| | Fura-2 | 1 | 1993 | 19 | 0.030 |
Why?
| | Blood Pressure Monitoring, Ambulatory | 1 | 2014 | 84 | 0.030 |
Why?
| | Electrodes | 1 | 1994 | 103 | 0.030 |
Why?
| | Vegetables | 1 | 2014 | 147 | 0.030 |
Why?
| | Aged, 80 and over | 1 | 2025 | 7033 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1009 | 0.030 |
Why?
| | Electric Stimulation | 1 | 1994 | 267 | 0.030 |
Why?
| | Surveys and Questionnaires | 1 | 2024 | 5362 | 0.020 |
Why?
| | Tetraethylammonium | 1 | 1991 | 17 | 0.020 |
Why?
| | Cadmium | 1 | 1991 | 67 | 0.020 |
Why?
| | Hybrid Cells | 1 | 2009 | 50 | 0.020 |
Why?
| | Electron Transport | 1 | 2009 | 112 | 0.020 |
Why?
| | Neurogenesis | 1 | 2009 | 126 | 0.020 |
Why?
| | Synaptic Transmission | 1 | 2009 | 258 | 0.020 |
Why?
| | Body Mass Index | 1 | 2014 | 2261 | 0.020 |
Why?
| | Electron Transport Complex I | 1 | 2006 | 38 | 0.020 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2006 | 133 | 0.020 |
Why?
| | Hypertrophy, Left Ventricular | 1 | 2006 | 126 | 0.010 |
Why?
| | Fatal Outcome | 1 | 2006 | 300 | 0.010 |
Why?
| | Aortic Coarctation | 1 | 2006 | 82 | 0.010 |
Why?
| | DNA Mutational Analysis | 1 | 2006 | 384 | 0.010 |
Why?
| | Avian Proteins | 1 | 2004 | 20 | 0.010 |
Why?
| | Cricetulus | 1 | 2004 | 104 | 0.010 |
Why?
| | CHO Cells | 1 | 2004 | 150 | 0.010 |
Why?
| | Cricetinae | 1 | 2004 | 275 | 0.010 |
Why?
| | Organ Specificity | 1 | 2004 | 291 | 0.010 |
Why?
| | Oocytes | 1 | 2004 | 175 | 0.010 |
Why?
| | Streptomycin | 1 | 2001 | 16 | 0.010 |
Why?
| | Base Sequence | 1 | 2004 | 2135 | 0.010 |
Why?
| | Amino Acid Sequence | 1 | 2004 | 2040 | 0.010 |
Why?
| | Molecular Sequence Data | 1 | 2004 | 2819 | 0.010 |
Why?
| | Disease Models, Animal | 1 | 2009 | 3937 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2009 | 5272 | 0.010 |
Why?
| | Cell Line | 1 | 2004 | 2731 | 0.010 |
Why?
| | Mutation | 1 | 2009 | 3689 | 0.010 |
Why?
| | RNA | 1 | 2004 | 880 | 0.010 |
Why?
| | Cochlea | 1 | 1997 | 100 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2006 | 5687 | 0.010 |
Why?
| | Middle Aged | 1 | 2014 | 30889 | 0.010 |
Why?
| | Homeostasis | 1 | 1996 | 603 | 0.010 |
Why?
| | Infant | 1 | 2006 | 8914 | 0.010 |
Why?
|
|
Rennie's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|